Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NNC0385-0434 in Renal Impairment
NCT05094934Phase 1Terminated
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NNC0385-0434 in hypercholesterolemia, sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 to 24 Hours. Started Nov 2021; status: terminated.
02
Drugs
NNC0385-0434
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05094934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094934.